DRC Launches Tumaini Ebola Vaccine Trial Amid 4,600-Death Bundibugyo Outbreak
WHO has begun the Tumaini Phase II/III trial in Bunia, eastern DRC, to test vaccines against the Bundibugyo strain of Ebola
In Brief
- •WHO has begun the Tumaini Phase II/III trial in Bunia, eastern DRC, to test vaccines against the Bundibugyo strain of Ebola
- •The trial will evaluate the existing Ervebo vaccine and two new Bundibugyo‑specific candidates from Moderna and Oxford/Serum Institute
- •As of 21 October, the outbreak has 9,552 confirmed cases and 4,602 deaths in the DRC
- •The study uses an adaptive platform and ring‑vaccination approach to assess safety, immune response and effectiveness
- •CEPI has committed $4.17 million to support research and the trial’s operations
Why It Matters
The Bundibugyo outbreak is the largest recorded for this Ebola species, and no vaccine has yet been approved. By testing Ervebo and novel candidates, the Tumaini trial seeks to determine whether existing vaccines can cross‑protect and to identify effective options for future outbreaks. Successful results could accelerate vaccine deployment and inform global preparedness strategies for emerging Ebola strains.
Key Details
- Trial Start Date
- 23 October 2026
- Number of Cases
- 9,552
- Number of Deaths
- 4,602
- Vaccine Candidates
- Ervebo, Moderna Bundibugyo, Oxford/Serum Institute Bundibugyo
- Funding Amount
- $4.17 million
- Trial Phase
- Phase II/III
Context & Background
Bundibugyo virus is a distinct Ebola species that has no approved vaccine; the current outbreak is the largest recorded for this strain.
Original Reporting & Sources
VNews is an independent briefing product. Original reporting remains credited to the following publishers:
This brief was synthesized automatically using attributed third-party reporting. VNews is a digital news publication produced under the VContent Group brand and operated by Francis Vincent Sunday in Ghana, independent from the publishers cited above. Read our AI Transparency Policy and Editorial & Corrections Policy.